Germany-based Wellington Partners has closed its fifth life sciences fund with a capital raise of €210 million for investments in companies developing medicines, devices, diagnostics and digital technologies. The new fund will primarily target opportunities in Europe.
It expects to invest in approximately 15 to 20 companies with a particular focus on German-speaking geographies. It will however also consider opportunities in North America and Asia.